Merck Succession
Executive Summary
Chairman Roy Vagelos reiterates Nov. 1, 1994 resignation date. Medco Chairman Marty Wygod is not a candidate to succeed, Vagelos tells annual meeting. Merck board -- nine outsiders and Vagelos and Wygod -- is well into succession issue, Vagelos reports. The Merck chairman -- an inveterate recruiter and talent selector -- has made inquiries outside the company about potential senior managers in the past year. A board dominated by outsiders may also be tempted to look beyond current management without a clear heir- apparent. Exec VP Edward Scolnick (research) and Senior VP-CFO Judy Lewent have been given the most visible outside roles as spokespeople for the firm in recent months
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth